Ibrutinib Plus Rituximab May Fight High-Risk CLL

Ibrutinib plus rituximab show promise for patients with high-risk chronic lymphocytic leukaemia...

ESMO members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.